Sex, drugs & stuttering

Pagoclone is turning out to be a wonder drug. Now Indevus, the company that owns Pagoclone, wants to test the drug to prevent "un-blocking", namely premature ejaculation!! So if you are a pre-ejaculating stutterer, Pagoclone solves two problems in one go! Seducing her with smooth speech, and standing power...

Here is the text:

Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that it has filed a New Patent Application with the U.S. Patent Office covering the use of pagoclone as a treatment for premature ejaculation (PE). The patent filing is based on evidence of pharmacologic activity contained in the Company's existing clinical databases.

"Premature ejaculation is one of the most common sexual dysfunctions in men, affecting approximately 30% of the adult male population," stated Glenn L. Cooper, M.D., chairman, president and chief executive officer of Indevus. "There are currently no approved oral drugs in the United States for the treatment of PE. The normal ejaculatory response is controlled by multiple neurotransmitters, including serotonin and GABA. There is evidence that drugs that stimulate or increase the levels of GABA in the brain may delay the ejaculatory response."

"Pagoclone is a selective, non-sedating GABA-A receptor partial agonist, studied extensively in the past for anxiety disorders and currently being studied by Indevus in a Phase II trial for the treatment of stuttering," continued Dr. Cooper. "We have found evidence within our existing database that patients have described ejaculatory delay on pagoclone. Based on these observations and the pharmacologic rationale, we intend to form an internal project team to explore the clinical and regulatory path to proof of concept studies of pagoclone as an on-demand oral therapy for men with PE. Pagoclone for PE would be an excellent strategic addition to our urology and men's health franchise."